Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.84B | 1.95B | 1.94B | 1.76B | 1.42B | Gross Profit |
686.03M | 705.64M | 612.65M | 594.64M | 513.44M | EBIT |
194.71M | 214.50M | 144.64M | 150.47M | 127.07M | EBITDA |
194.71M | 290.11M | 239.42M | 253.22M | 138.74M | Net Income Common Stockholders |
116.64M | 112.75M | -17.81M | 121.37M | 39.66M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
188.88M | 194.53M | 180.96M | 165.18M | 181.83M | Total Assets |
2.61B | 2.71B | 2.82B | 2.96B | 2.89B | Total Debt |
727.20M | 788.97M | 979.77M | 919.68M | 915.11M | Net Debt |
538.32M | 594.44M | 798.81M | 754.51M | 733.27M | Total Liabilities |
1.26B | 1.33B | 1.54B | 1.57B | 1.57B | Stockholders Equity |
1.35B | 1.38B | 1.28B | 1.39B | 1.32B |
Cash Flow | Free Cash Flow | |||
215.86M | 240.22M | 13.26M | 27.48M | 160.49M | Operating Cash Flow |
204.58M | 279.02M | 41.79M | 48.93M | 178.39M | Investing Cash Flow |
-76.42M | -27.62M | -40.19M | -49.13M | -71.39M | Financing Cash Flow |
-122.66M | -238.61M | 24.67M | -13.46M | -75.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $7.17B | 18.50 | 21.49% | ― | 1.77% | 47.48% | |
77 Outperform | $14.67B | 22.54 | 25.61% | 1.70% | 0.12% | 24.30% | |
75 Outperform | $10.05B | 11.34 | 16.11% | 3.74% | 1.91% | 2.94% | |
68 Neutral | $2.22B | 19.29 | 8.49% | 1.50% | -5.82% | 3.75% | |
61 Neutral | $2.97B | 27.59 | 6.35% | 1.62% | 0.99% | -27.62% | |
57 Neutral | $2.78B | 21.03 | 0.18% | 2.75% | -4.35% | -115.63% | |
47 Neutral | $2.66B | -3.14 | -22.17% | 3.33% | 3.73% | -29.29% |
Quaker Chemical Corporation’s Compensation and Human Resources Committee has granted long-term incentive equity compensation awards to its executives, Tom Coler and Jeewat Bijlani, in the form of restricted stock units (RSUs) under its Long-Term Performance Incentive Plan. These RSUs are subject to a performance modifier based on the company’s total shareholder return relative to the S&P 1500 Chemicals Index, with vesting adjustments ranging from 75% to 125% of the target number, depending on performance over a three-year period.